Bio-Path Holdings Inc (BPTH)

0.42
NASDAQ : Health Care
Prev Close 0.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.42 / 2.83
Avg Volume 171.90K
Exchange NASDAQ
Shares Outstanding 95.65M
Market Cap 41.13M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bio-Path Holdings Presents Results Showing Potential Of BP1002 As Treatment For Aggressive Non-Hodgkin's Lymphoma

Bio-Path Holdings Presents Results Showing Potential Of BP1002 As Treatment For Aggressive Non-Hodgkin's Lymphoma

- In Vivo and Preclinical Data Presented at AACR Annual Meeting -

Bio-Path Holdings Reports Full Year 2016 Financial Results

Bio-Path Holdings Reports Full Year 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Appoints Dr. Craig Hooper To Scientific Advisory Board

Bio-Path Holdings Appoints Dr. Craig Hooper To Scientific Advisory Board

Renowned neuroimmunology researcher joins SAB to advance DNAbilize™ technology in glioblastoma

Short Interest In Bio-Path Holdings Expands By 23.3%

Short Interest In Bio-Path Holdings Expands By 23.3%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 544,221 share increase in total short interest for Bio-Path Holdings, Inc. , to 2,876,240, an increase of 23.34% since 01/13/2017.

Bio-Path Holdings Reports Third Quarter 2016 Financial Results

Bio-Path Holdings Reports Third Quarter 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Reports Second Quarter 2016 Financial Results

Bio-Path Holdings Reports Second Quarter 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University For Systemic Antisense Immunotherapy Treatment For Brain Cancer

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University For Systemic Antisense Immunotherapy Treatment For Brain Cancer

Sponsored Research Agreement will Evaluate DNAbilize™ Technology as a Cancer Vaccine to Activate Patients' Immune Systems to Fight Cancer

Bio-Path Holdings Reports Promising Data From Phase I And Phase II Clinical Trials Of BP1001 In Blood Cancers Presented At ASCO 2016

Bio-Path Holdings Reports Promising Data From Phase I And Phase II Clinical Trials Of BP1001 In Blood Cancers Presented At ASCO 2016

Five of six evaluable patients achieved remission in safety segment of the Phase II combination therapy trial of BP1001, including three complete remissions and two partial remissions

Bio-Path Holdings Reports First Quarter 2016 Financial Results

Bio-Path Holdings Reports First Quarter 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET